SM
PSTV icon

Sabby Management’s Plus Therapeutics PSTV Stock Holding History

Sabby Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-624
Closed -$562K – 100
2019
Q4 		$562K Buy
624
+321
+106% +$294K 0.16% 33
2019
Q3 		$389K Buy
+303
New +$1.09M 0.21% 49
2017
Q3 		– Sell
-9
Closed -$1.79M – 199
2017
Q2 		$1.79M Buy
9
+2
+29% +$404K 0.12% 75
2017
Q1 		$2.03M Sell
7
-2
-22% -$617K 0.11% 90
2016
Q4 		$2.49M Hold
9
– – 0.15% 89
2016
Q3 		$3.58M Sell
9
-1
-10% -$388K 0.13% 92
2016
Q2 		$4.11M Buy
10
+7
+233% +$4.18M 0.21% 64
2016
Q1 		$14.3M Sell
3
-3
-50% -$1.5M 0.72% 22
2015
Q4 		$3.19M Buy
6
+5
+500% +$4.69M 0.18% 87
2015
Q3 		$1M Sell
1
-1
-50% -$1.17M 0.04% 235
2015
Q2 		$2.99M Buy
+2
New +$4.58M 0.11% 128
2015
Q1 		– Sell
-1
Closed -$2.19M – 320
2014
Q4 		$1.02K Hold
1
– – 0.03% 157
2014
Q3 		$2.36K Hold
1
– – 0.09% 99
2014
Q2 		$4.29M Buy
+1
New +$6.73M 0.18% 67

Other funds holding PSTV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
FP
Financial Perspectives Minneapolis, Minnesota $411M AUM 26.27% 1-Year Est. Return

Sabby Management's PSTV Position: Q1 2020 in Review

Sabby Management sold out of Plus Therapeutics (PSTV) in Q1 2020, closing a stake of 624 shares — an estimated $562K sold.

Sabby Management first reported a position in PSTV in Q2 2014 and held it in 14 quarters. The position peaked at $14.3M in Q1 2016. 5 funds tracked by Wall St. Rank hold PSTV as of Q1 2020.

  • Sabby Management reported no remaining Plus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Sabby Management sold 624 Plus Therapeutics shares in Q1 2020, an estimated $562K.
  • Sabby Management first reported a position in Plus Therapeutics in Q2 2014 and held it in 14 quarters.
  • Sabby Management's Plus Therapeutics position peaked at $14.3M in Q1 2016.
  • 5 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2020.

Based on Sabby Management's 13F filing for Q1 2020, filed 15 May 2020.